Chlamydia Infection Diagnostic & Therapeutic Market - Forecast(2024 - 2030)

Report Code: HCR 0990 Report Format: PDF + Excel

Chlamydia Infection Diagnostic & Therapeutic Market Overview

Chlamydia Infection Diagnostic & Therapeutic Market Size is estimated to reach $1.1 billion by 2027 and is poised to grow at a CAGR of 6.1% over the forecast period of 2022-2027. Chlamydia is a common form of STD (Sexually Transmitted Disease) that can cause infection in both males and females. Chlamydia can also cause a potentially fatal ectopic pregnancy (pregnancy that occurs outside the womb). Chlamydia can be diagnosed with nucleic acid amplification tests (NAATs), cell cultures and other types of tests. Chlamydia can usually be effectively treated with the right dosage of antibiotics. The chlamydia infection diagnostic and therapeutic market value unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities, especially in developing economies. The growing public health infrastructure and knowledge base related to STDs would drive the Chlamydia Infection Diagnostics & Therapeutics industry in the forecast period of 2022-2027.

Chlamydia Infection Diagnostic & Therapeutic Market Report Coverage

The report: “Chlamydia Infection Diagnostic & Therapeutic Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Chlamydia Infection Diagnostic & Therapeutic Market.

By Diagnostics: Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, Culture Tests, Serology Tests and others.
By Therapeutics: Macrolides, Quinolones, Sulphonamides, Tetracycline and Aminopenicillins. 
By End-users: Diagnostics (Hospitals, Specialty Clinics and Diagnostic Centers) and Therapeutics (Hospital Pharmacies, Drug Stores, Retail Pharmacies and Online Pharmacies).
By Geography: North America (the US, Canada and Mexico), Europe (Germany, the UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share owing to the growing Chlamydia Infection Diagnostics and Therapeutics market in the U.S. It is due to intensive diagnostic and preventive guidelines for STDs in the country. However, Asia-Pacific is expected to offer lucrative growth opportunities owing to a rampant adoption of western practices loomed by increasing awareness related to STDs.
  • The global practices and strategies aimed to reduce the incidence and impact of Chlamydia along with rampant growth in the prevention strategies would continue to act as a major market driver. However, due to societal trends, the market would face challenges.
  • A detailed analysis of the strengths, weaknesses, opportunities and threats would be provided in the Chlamydia Infection Diagnostic and Therapeutic Market Report.

Chlamydia Infection Diagnostic & Therapeutic Market Share, by Region(%), 2021

Chlamydia Infection Diagnostic & Therapeutic Market

For more details on this report - Request for Sample

Chlamydia Infection Diagnostic & Therapeutic Market - By Diagnostics

Chlamydia Infection Diagnostics & Therapeutics Industry based on diagnostics can be further segmented into Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, Culture Tests, Serology Tests and others. Nucleic Acid Amplification Tests (NAATs) dominated the market in 2021, due to higher sensitivity and specificity than other chlamydia tests available in the market. Moreover, NAAT is estimated to be the fastest growing segment with a CAGR of 6.7% over the forecast period of 2022-2027. It is because of the adaptability of tests to be used with both urine and vaginal samples for women. Moreover, various point-of-care diagnostics help control the growing number of chlamydia cases. As per CDC, within the US, 97.72 thousand cases of Chlamydia were found in New York.

Chlamydia Infection Diagnostic & Therapeutic Market - By Therapeutics

Chlamydia Infection Diagnostics & Therapeutics Industry based on therapeutics can be further segmented into Macrolides, Quinolones, Sulphonamides, Tetracycline and Aminopenicillins. Macrolides held a dominant market share in 2021 and are estimated to be the fastest growing segment with a CAGR of 7.4% over the forecast period of 2022-2027. As per NHS UK, nearly 95% of the infections can be controlled by the usage of azithromycin and doxycycline. This medical class is a highly safe antibiotic class. That is the reason it is widely recognized and recommended. Various research published in research papers highlights how the particular medicine class can cure the symptoms within a week of regular treatment, with minimal damage to other body parts.

Chlamydia Infection Diagnostic & Therapeutic Market - By Geography

Chlamydia Infection Diagnostics & Therapeutics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America dominated the market in 2021, with a share of 37%. Intensive diagnostic capabilities and alignment with the future aim to reduce the overall incidence of the disease through therapeutics and diagnostic methods. This allows the market to hold a strong share. However, Asia-Pacific is estimated to grow at a significant CAGR over the forecast period of 2022-2027, owing to its vast potential to quickly adapt to new therapies and the presence of several strong economies. As per the recent Parliamentary Budget of India, nearly INR 82,000 crore was provided for overall healthcare.

Chlamydia Infection Diagnostic & Therapeutic Market Drivers

The Growing Incidence of Chlamydia across the Globe:

Chlamydia has historically been a highly prevalent form of STD within the US. As per the Sexually Transmitted Disease Surveillance report of 2020, chlamydia had nearly 1.6 million cases in 2020. Furthermore, CDC adds that the overall incidence of this STD has reduced marginally. However, the overall impact of the disease remains extremely high in the category of STDs. The numbers for chlamydia stand at nearly 250,000 cases in Europe as per the European Center for Disease Prevention and Control. The incidence continues to increase in the regions of Asia as well, which would positively impact the market growth.

The Rising Support from the Global Agency:

As per a 2020 WHO report, the agency plans to eradicate major STIs from the globe or reduce the total prevalence by nearly 90% of the current standards. Moreover, the major increase in the diagnostic and treatment of chlamydia across the globe has been a growth propeller. Various councils and societies are created within colleges and universities of the developed nations, whose primary aim is to promote the diagnosis and treatment of any form of STDs, especially chlamydia which has long-lasting effects on the female body. Additionally, various governments across developing nations are trying to curb the effects of STDs on society. As per CDC, direct lifetime expenses of new STIs cost nearly $16 billion to the U.S. healthcare system.

Chlamydia Infection Diagnostic & Therapeutic Market Challenges

Societal Pressures within Developing Countries along with COVID-19-induced Limited Testing Capacities:

Probably no set of diseases is more stigmatized than sexually transmitted diseases (STDs) — even though they’re also some of the most common infections across the spectrum of humanity. CDC recorded a lower number of instances in the U.S. for 2020 and 2021. However, they have identified the role of lower testing capacities and diagnostic centers’ alignment due to COVID-19 as a major reason for the lower number of registered cases. Developing societies, such as India which records nearly 30 million STI infections each year report huge stigma, which reduces the market value as per Chlamydia Infection Diagnostic & Therapeutic market research.

Chlamydia Infection Diagnostic & Therapeutic Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Chlamydia Infection Diagnostic & Therapeutic Market. The top 10 companies in the Chlamydia Infection Diagnostic & Therapeutic Market are:

  1. Abbott Laboratory
  2. Becton, Dickinson and Company
  3.  Bio-Rad Labs
  4. Danaher Corporation
  5. DiaSorin SpA
  6. F. Hoffman La-Roche Ltd
  7. Hologic Inc.
  8. Quidel Corporation
  9. Savyon Diagnostics
  10. Trinity Biotech Plc.

Recent Developments

  • In September 2022, Chlamydia’s stealth cloaking device was identified by Duke University Researchers. As per the research, microbial proteins around this STD allow the pathogen to hide undetected inside the host cells.
  • In May 2022, Becton, Dickinson and Company announced the launch of its new, fully-automated, high-throughput infectious disease molecular diagnostics platform in the US. The initial test on the new system is a single test that detects the most prevalent non-viral STD such as chlamydia trachomatis.
  • In April 2022, Chiricahua Community Health Centers, Inc. (CCHCI) announced a collaboration with The Body Agency Collective (TBAC) and Visby Medical, Inc. to improve sexually transmitted infection (STI) diagnosis. A new PCR machine known as Sexual Health Click Test would be utilized.

Relevant Titles

Cell-Free Fetal DNA Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis.
Report Code: HCR 0198

DNA Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis.
Report Code: HCR 0278

Molecular Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis.
Report Code: HCR 0068 

For more Lifesciences and Healthcare Market reports, please click here

1. Chlamydia Infection Diagnostic & Therapeutic Market - Overview    
    1.1 Definitions and Scope                                              
2. Chlamydia Infection Diagnostic & Therapeutic Market - Executive Summary
3. Chlamydia Infection Diagnostic & Therapeutic Market - Comparative Analysis
    3.1 Company Benchmarking - Key Companies                               
    3.2 Global Financial Analysis - Key Companies                          
    3.3 Market Share Analysis - Key Companies                              
    3.4 Patent Analysis                                                    
    3.5 Pricing Analysis                                                   
4. Chlamydia Infection Diagnostic & Therapeutic Market - Start-upCompanies Scenario Premium
    4.1 Investment                                                         
    4.2 Revenue                                                            
    4.3 Venture Capital and Funding Scenario                               
5. Chlamydia Infection Diagnostic & Therapeutic Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview                                      
    5.2 New Business and Ease of Doing Business Index                      
    5.3 Case Studies of Successful Ventures                                
6. Chlamydia Infection Diagnostic & Therapeutic Market - Forces      
    6.1 Market Drivers                                                     
    6.2 Market Constraints/Challenges                                      
    6.3 Porter's Five Force Model                                          
        6.3.1 Bargaining power of suppliers                                    
        6.3.2 Bargaining powers of customers                                   
        6.3.3 Threat of new entrants                                           
        6.3.4 Rivalry among existing players                                   
        6.3.5 Threat of substitutes                                            
7. Chlamydia Infection Diagnostic & Therapeutic Market – Strategic Analysis
    7.1 Value Chain Analysis                                               
    7.2 Opportunities Analysis                                             
    7.3 Market Life Cycle                                                  
8. Chlamydia Infection Diagnostic & Therapeutic Market – by Diagnostics
    8.1 Nucleic Acid Amplification Tests (NAATs)                           
    8.2 Direct Fluorescent Tests                                           
    8.3 Culture Test                                                       
    8.4 Serology Test                                                      
    8.5 Others                                                             
9. Chlamydia Infection Diagnostic & Therapeutic Market – by Therapeutics
    9.1 Macrolides                                                         
    9.2 Quinolones                                                         
    9.3 Sulphonamides                                                      
    9.4 Tetracycline                                                       
    9.5 Aminopenicillins                                                   
10. Chlamydia Infection Diagnostic & Therapeutic Market – by End-users
    10.1 Diagnostics                                                       
        10.1.1 Hospitals                                                       
        10.1.2 Specialty Clinics                                               
        10.1.3 Diagnostic Centers                                              
    10.2 Therapeutics                                                      
        10.2.1 Hospital Pharmacies                                             
        10.2.2 Drug Stores                                                     
        10.2.3 Retail Pharmacies                                               
        10.2.4 Online Pharmacies                                               
11. Chlamydia Infection Diagnostic & Therapeutic Market - by Geography
    11.1 North America                                                     
        11.1.1 The US                                                          
        11.1.2 Canada                                                          
        11.1.3 Mexico                                                          
    11.2 Europe                                                            
        11.2.1 The UK                                                          
        11.2.2 Germany                                                         
        11.2.3 France                                                          
        11.2.4 Italy                                                           
        11.2.5 Spain                                                           
        11.2.6 Russia                                                          
        11.2.7 The Rest of Europe                                              
    11.3 Asia-Pacific                                                      
        11.3.1 China                                                           
        11.3.2 India                                                           
        11.3.3 Japan                                                           
        11.3.4 South Korea                                                     
        11.3.5 Australia & New Zealand                                         
        11.3.6 The Rest of Asia-Pacific                                        
    11.4 South America                                                     
        11.4.1 Brazil                                                          
        11.4.2 Argentina                                                       
        11.4.3 Chile                                                           
        11.4.4 Colombia                                                        
        11.4.5 The Rest of South America                                       
    11.5 The Rest of the World                                             
        11.5.1 The Middle East                                                 
        11.5.2 Africa                                                          
12. Chlamydia Infection Diagnostic & Therapeutic Market - Entropy    
13. Chlamydia Infection Diagnostic & Therapeutic Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis                                             
        13.1.1 Market Share by Region – Key companies                          
        13.1.2 Market Share by Countries – Key Companies                       
    13.2 Competition Matrix                                                
    13.3 Best Practices for Companies                                      
14. Chlamydia Infection Diagnostic & Therapeutic Market – Key Company List by Country Premium Premium
15. Chlamydia Infection Diagnostic & Therapeutic Market - Company Analysis
    15.1 Company 1                                                         
    15.2 Company 2                                                         
    15.3 Company 3                                                         
    15.4 Company 4                                                         
    15.5 Company 5                                                         
    15.6 Company 6                                                         
    15.7 Company 7                                                         
    15.8 Company 8                                                         
    15.9 Company 9                                                         
    15.10 Company 10                                                       
* "Financials would be provided to private companies on a best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.